Understanding how the retinoblastoma protein is controlled in cancer cells
Regulation of the retinoblastoma (Rb) tumor suppressor by the ubiquitin-proteasome system
['FUNDING_FELLOWSHIP'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-10825894
This study is looking at how a protein that helps prevent cancer, called Rb, is controlled in breast cancer, especially for patients who are being treated with specific medications, and it hopes to find better ways to make these treatments work more effectively for those with hormone-receptor positive, HER2-negative metastatic breast cancer.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-10825894 on ClinicalTrials.gov |
What this research studies
This research investigates the regulation of the retinoblastoma (Rb) protein, a crucial tumor suppressor that helps control cell growth and division. The study focuses on how the ubiquitin-proteasome system affects Rb levels, particularly in the context of breast cancer treatment with Cdk4/6 inhibitors. By exploring the mechanisms that lead to resistance against these inhibitors, the research aims to identify new strategies to enhance treatment effectiveness for patients. Patients may benefit from insights that could lead to improved therapies for hormone-receptor positive, HER2-negative metastatic breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with hormone-receptor positive, HER2-negative metastatic breast cancer who are being treated with Cdk4/6 inhibitors.
Not a fit: Patients with other types of cancer or those not receiving Cdk4/6 inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for breast cancer patients who currently face resistance to existing therapies.
How similar studies have performed: Other research has shown promising results in targeting the ubiquitin-proteasome system to enhance cancer treatment, suggesting that this approach may be effective.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: APONTE, AMY — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: APONTE, AMY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.